BURLINGAME, Calif.—Ablexis LLC and the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) have struck up a non-exclusive, perpetual license agreement for access to the AlivaMab Mouse for antibody drug discovery and development. With this deal, the Tri-I TDI gains its own colony of AlivaMab Mouse and broad rights to use it for antibody drug discovery and development. The Tri-I TDI is an initiative by Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine that discovers small molecules and biologics for proof-of-concept studies. Financial details were not disclosed.